Vetter contributes to commercial launches of eight customer products in 2023

- Vetter successfully brought eight customer drugs to market after supporting them through the development phases 

- As an established leader in commercial fill and finish, Vetter has evolved as a trusted provider of drug product development services 

- New molecules candidates brought to Vetter in the clinic receive strategic counsel and experienced support to guide their path to market and beyond 

Vetter, a leading globally operating contract development and manufacturing organization (CDMO) announces the successful commercialization of eight customer drug products as of the completion of 2023. The products were supported by the comprehensive portfolio of the Vetter Development Service during their drug development phases. The drug products that reached the world market are used in oncology and to treat autoimmune and cardiovascular diseases, among others. Their nature and administration vary widely, ranging from emergency medications to long-term and life-enhancing therapies for patients. The drugs also vary in delivery methods, which include self-administration for at-home care and administration by healthcare professionals.